ApoGen Biotechnologies is developing novel oncology therapeutics targeting the key drivers of mutation and cancer genomic evolution to overcome drug resistance. Our lead target is APOBEC3B (A3B), a DNA cytosine deaminase and an important endogenous source of DNA mutation in cancer. A3B was recently identified as a dominant source of the characteristic C-to-T mutational pattern and higher overall mutational load seen in numerous cancers. Elevated levels of A3B were shown to be a key driver in the formation of cancers including breast, head and neck, lung, bladder, cervical, ovarian, myeloma, and some blood cancers. ApoGen’s drug discovery and development efforts are directed toward highly selective and potent small molecule inhibitors of A3B. These inhibitors aim to slow or stop cancer genome mutation and the development of drug resistance, potentially increasing the effectiveness of current and future therapies.
Seattle, US
Size (employees)
3 (est)
ApoGen Biotechnologies was founded in 2014 and is headquartered in Seattle, US
Report incorrect company information

ApoGen Biotechnologies Office Locations

ApoGen Biotechnologies has an office in Seattle
Seattle, US (HQ)
200 1616 Eastlake Ave E
Show all (1)
Report incorrect company information

ApoGen Biotechnologies Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$7 m

Latest funding size

$7 m

Time since last funding

2 years ago


ApoGen Biotechnologies's latest funding round in December 2016 was reported to be $7 m. In total, ApoGen Biotechnologies has raised $7 m
Show all financial metrics
Report incorrect company information